Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2017 Earnings
30 Octobre 2017 - 9:35PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on the development of curative therapeutics using
CRISPR/Cas9 technology, will present third quarter 2017 results to
investors and analysts in a conference call on October 31, 2017 at
8:30am EDT, hosted by Nessan Bermingham, Ph.D., Chief Executive
Officer and Founder, John Leonard, M.D., Executive Vice President,
R&D, and Graeme Bell, Chief Financial Officer. The analyst and
investor presentation can be downloaded starting at 8:00am EDT from
the Investor Relations section of the company’s website at
www.intelliatx.com. A replay of the call will be available on
Intellia’s website, beginning on October 31 at 11:00am EDT, 2017.
To participate on the day of the call:
- U.S. callers should dial 888-752-0423 and use Conference ID#
9089048, approximately five minutes before the call.
- International callers should dial +1 918-398-4936 and use
Conference ID# 9089048, approximately five minutes before the
call.
To listen to the replay:
- U.S. callers should dial 855-859-2056, Conference ID#
9089048.
- International callers should dial +1 404-537-3406, Conference
ID# 9089048.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on the development of proprietary, pot curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with
a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our
leading intellectual property portfolio, puts us in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets
Intellia Contacts:
Investor Contact: Lindsey Trickett Vice
President, Investor Relations +1 857-285-6211
lindsey.trickett@intelliatx.com
Media Contact:Jennifer Mound Smoter Senior Vice
President, External Affairs & Communications +1
857-706-1071jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024